vimarsana.com
Home
Live Updates
Y-mAbs Reports First Quarter 2023 Financial Results and Rece
Y-mAbs Reports First Quarter 2023 Financial Results and Rece
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022Management updates 2023 financial guidance, now... | May 8, 2023
Related Keywords
Russia ,
United States ,
New York ,
Ukraine ,
,
Company Quarterly Report On Form ,
Company Pediatric Investigational Plan ,
Y Mabs Therapeutics Inc ,
Securities Exchange ,
European Medicines Agency ,
Globenewswire Inc ,
Company Annual Report On Form ,
Abs Therapeutics ,
Interim Chief Executive ,
Recent Corporate ,
Medicines Agency ,
Pediatric Investigational Plan ,
Conference Call ,
Securities Act ,
Securities Exchange Act ,
Annual Report ,
Quarterly Report ,
Net Loss ,
Y Mabs Therapeutics ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
1 ,
023 ,
Record ,
Pet ,
Product ,
Revenues ,
F ,
Driving ,
Toy ,
Growth ,
End ,
Sequential ,
Increase ,
Ompared ,
O ,
4 ,
022management ,
Updates ,
Inancial Ymab Us9842411095 ,